Treatment with cabozantinib, a multi-targeted kinase inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 and several other kinases (i.e., AXL, MET, RET, KIT, FLT3, ROS1, MER, TYRO3, TRKB, and TIE-2), was shown to reduce prostate cancer growth in the bone, by suppressing the osteoblastic activity, a prerequisite for bone invasion, in an in vivo preclinical model. The gene discussed is KDR; the disease is Familial prostate cancer.